Asthma

Inhibiting the calcium release-activated calcium channel found to be an effective approach to limit allergic asthma without affecting the body’s defenses against influenza.

Dupilumab is used as a maintenance therapy when added to other asthma medications.

Aobbiy is a lung expansion and mucus relief device that aids in mucus removal to help clear the airway.

FDA approved dexamethasone tablets USP 1.5mg, 4mg and 6mg, providing a new generic alternative to the steroid Decadron.

Subcutaneous immunotherapy-induced antibodies may serve as a potential allergen-targeted biologics candidate for the treatment of allergic asthma.

ProAir Digihaler Inhalation Powder is indicated for the treatment or prevention of bronchospasm in those with reversible obstructive airway disease and for the prevention of exercise-induced bronchospasm.

Study findings provide evidence that preventative antibiotics improve health outcomes for babies and mothers, investigator say.

The study marks the first time an albuterol/budesonide fixed-dose combination rescue medication has reduced severe exacerbations, the company said.

The combination of albuterol/budesonide shows promise in lowering the risk of severe exacerbations and improved lung function compared to albuterol as a rescue inhaler in patients with asthma.

Second analysis indicates that parents of children with food allergies became less anxious during the pandemic.

National Asthma and Allergy Awareness Month highlights how pharmacists in all health care settings are in a unique position to improve management and outcomes of individuals with these conditions.

This month's OTC case studies focuses on asthma.

Asthma contributed most to the risk of high blood pressure and coronary heart disease.

Asmanex HFA is a corticosteroid indicated for the maintenance treatment of asthma as prophylactic therapy in patients 12 years of age and older

Singulair is a leukotriene receptor antagonist indicated for prophylaxis and chronic treatment of asthma.

Agency hopes green light for complex drug device combination improves competition and access more affordable medications.

Nucala is an IL-5 antagonist monoclonal antibody (immunoglobulin G1 kappa) for the add-on maintenance treatment of adult and pediatric patients with severe asthma and with an eosinophilic phenotype.

Study findings support the role of tezepelumab-ekko as a first-in-class treatment for a broad population of patients living with severe asthma, irrespective of biomarker levels.

Wixela Inhub is indicated for the treatment of asthma in patients 4 years of age and older and maintenance treatment of patients with chronic obstructive pulmonary disease.

Breo Ellipta is indicated for long-term, once-daily, maintenance treatment of airflow obstruction and reducing exacerbations in patients with chronic obstructive pulmonary disease.

Advair Diskus is indicated for the maintenance treatment of asthma and chronic obstructive pulmonary disease.

The study enrolled 214 patients, with 105 randomized to a risankizumab injection every 4 weeks over a 24-week period, while 109 patients received a placebo.

Dupilumab is indicated for the treatment of adult patients with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.

Benralizumab (Fasenra) is indicated for the add-on maintenance treatment of patients with severe asthma aged 12 years and older and with an eosinophilic phenotype.

Evidence of a causal relationship between the onset of allergic disease and mental health was limited, suggesting that the observational associations found were due to confounding or other forms of bias.

Ten quiz questions to assess your knowledge on common symptoms and treatments for asthma.

The approval is based on data from a phase 3 placebo-controlled trial that evaluated the efficacy and safety of dupilumab combined with standard-of-care therapy in children with uncontrolled moderate-to-severe asthma.

PT0271 improved lung function and reduced the risk of exacerbations in individuals with asthma.

A new study explores why individuals who suffer most from the condition have the worse symptoms at night.